{"id":"ipv-al-ssi","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine contains chemically inactivated poliovirus particles that cannot cause disease but trigger adaptive immune responses. The aluminum adjuvant enhances the immunogenicity of the vaccine by promoting T-cell and B-cell activation, leading to production of neutralizing antibodies against poliovirus. The vaccine is designed to provide protection against poliomyelitis through humoral and cellular immunity.","oneSentence":"IPV-Al SSI is an inactivated poliovirus vaccine formulated with aluminum adjuvant to stimulate immune response against poliovirus types 1, 2, and 3.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:07.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in pediatric and adult populations"}]},"trialDetails":[{"nctId":"NCT03032419","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2017-02-06","conditions":"Poliomyelitis","enrollment":1002},{"nctId":"NCT03025750","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2017-01-19","conditions":"Poliomyelitis","enrollment":800},{"nctId":"NCT02280447","phase":"PHASE1, PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2014-11-13","conditions":"Immunization, Booster","enrollment":240},{"nctId":"NCT02347423","phase":"PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2015-02","conditions":"Poliomyelitis","enrollment":824},{"nctId":"NCT03671616","phase":"PHASE3","title":"Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2018-05-15","conditions":"Poliomyelitis","enrollment":666}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IPV-Al SSI","genericName":"IPV-Al SSI","companyName":"Statens Serum Institut","companyId":"statens-serum-institut","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV-Al SSI is an inactivated poliovirus vaccine formulated with aluminum adjuvant to stimulate immune response against poliovirus types 1, 2, and 3. Used for Poliomyelitis prevention in pediatric and adult populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}